AskAt Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
7
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 9, 2027The maintenance fee for Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer (US 10,342,785) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
- 1 fee due Feb 27, 2027The maintenance fee for Use of EP4 receptor antagonists in the treatment of cartilage disease (US 10,391,086) comes due Feb 27, 2027. Unpaid by Aug 27, 2027, it lapses early.
- 1 fee due Jun 12, 2027The maintenance fee for Selective EP4 receptor antagonistic substance for treatment of cancer (US 11,840,530) comes due Jun 12, 2027. Unpaid by Dec 13, 2027, it lapses early.
- 1 fee due Sep 10, 2027The maintenance fee for Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer (US 10,583,129) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.
- 2 fees due Oct 7 to 23, 2027 · next Oct 7
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,776,885 | Benzimidazolone Compounds Having 5-HT4 Receptor Agonistic Activity In force · Medium confidence | In force | Medium confidence | |
| US 7,960,407 | Crystal Forms of an Imidazole Derivative In force · High confidence | In force | High confidence | |
| US 10,611,761 | Selective EP4 receptor antagonistic substance for treatment of cancer In force · From the USPTO record | In force | From the USPTO record | |
| US 10,947,235 | Selective EP4 receptor antagonistic substance for treatment of cancer In force · From the USPTO record | In force | From the USPTO record | |
| US 9,688,674 | Selective EP4 receptor antagonistic substance for treatment of cancer In force · From the USPTO record | In force | From the USPTO record | |
| US 8,921,391 | Selective EP4 receptor antagonistic substance for treatment of cancer In force · From the USPTO record | In force | From the USPTO record | |
| US 8,653,063 | N-substituted saturated heterocyclic sulfone compounds with CB2 receptor agonistic activity In force · From the USPTO record | In force | From the USPTO record | |
| US 8,980,922 | 5-HT4 Receptor Agonists for the Treatment of Dementia In force · High confidence | In force | High confidence | |
| US 11,840,530 | Selective EP4 receptor antagonistic substance for treatment of cancer In force · From the USPTO record | In force | From the USPTO record | |
| US 9,457,084 | Use of EP4 receptor antagonists in the treatment of IL-23 mediated diseases In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 21: 1 lapsed for an unpaid fee · 7 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 1 abandoned · 5 no status recorded